Healthpeak Properties (DOC) stands to benefit from increased clarity on the Federal Reserve’s policy path following President Trump’s nomination of Kevin Warsh as Fed chair. Market consensus now forecasts two quarter-point rate cuts in 2026, underpinning a lower cost of capital for REITs. DOC’s current dividend yield of approximately 7% is supported by an investment-grade credit rating and a fixed-rate debt portfolio with an average maturity of 5.2 years, insulating cash flows from near-term refinancing risk and enhancing distribution coverage in a stable rate environment.

In its Q4 2025 earnings release, Healthpeak reported Funds From Operations (FFO) of $0.56 per share on a same-store net operating income (SS NOI) increase of 4.1% year-over-year. Total revenue rose 3.8% driven by higher occupancy in life-sciences properties, now 98.3% leased, and rent escalations averaging 2.5% across the portfolio. The company completed $400 million in targeted dispositions at a 6.8% cap rate, redeploying proceeds into $250 million of accretive development starts focused on lab space in Boston and San Francisco, where market rents exceed $80 per square foot.

Healthpeak’s recent strategic pivot involves spinning off its senior housing assets into a new externally managed vehicle, Janus Living, slated to acquire $2.1 billion of properties. While this move aims to streamline the core life-sciences and medical-office platform, the external management structure and a dual-CEO governance model introduce significant execution risk. DOC currently trades at a 15%–20% discount to net asset value (NAV), reflecting investor skepticism after underperforming the MSCI REIT Index by 12% over the past twelve months and missing its FFO growth target of 5% for fiscal 2025.